Frontal cortex and striatal cellular and molecular pathobiology in individuals with Down syndrome with and without dementia
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
Although, by age 40, individuals with Down syndrome (DS) develop amyloid-β (Aβ) plaques and tau-containing neurofibrillary tangles (NFTs) linked to cognitive impairment in Alzheimer’s disease (AD), not all people with DS develop dementia. Whether Aβ plaques and NFTs are associated with individuals with DS with (DSD +) and without dementia (DSD −) is under-investigated. Here, we applied quantitative immunocytochemistry and fluorescent procedures to characterize NFT pathology using antibodies specific for tau phosphorylation (pS422, AT8), truncation (TauC3, MN423), and conformational (Alz50, MC1) epitopes, as well as Aβ and its precursor protein (APP) to frontal cortex (FC) and striatal tissue from DSD + to DSD − cases. Expression profiling of single pS422 labeled FC layer V and VI neurons was also determined using laser capture microdissection and custom-designed microarray analysis. Analysis revealed that cortical and striatal Aβ plaque burdens were similar in DSD + and DSD − cases. In both groups, most FC plaques were neuritic, while striatal plaques were diffuse. By contrast, FC AT8-positive NFTs and neuropil thread densities were significantly greater in DSD + compared to DSD −, while striatal NFT densities were similar between groups. FC pS422-positive and TauC3 NFT densities were significantly greater than Alz50-labeled NFTs in DSD + , but not DSD − cases. Putaminal, but not caudate pS422-positive NFT density, was significantly greater than TauC3-positive NFTs. In the FC, AT8 + pS422 + Alz50, TauC3 + pS422 + Alz50, pS422 + Alz50, and TauC3 + pS422 positive NFTs were more frequent in DSD + compared to DSD- cases. Single gene-array profiling of FC pS422 positive neurons revealed downregulation of 63 of a total of 864 transcripts related to Aβ/tau biology, glutamatergic, cholinergic, and monoaminergic metabolism, intracellular signaling, cell homeostasis, and cell death in DSD + compared DSD − cases. These observations suggest that abnormal tau aggregation plays a critical role in the development of dementia in DS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Neuropathological alterations in Alzheimer disease
Serrano-Pozo, A., Frosch, M. P., Masliah, E., & Hyman, B. T. (2011) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006189 · Cited by 3,345 · cited 3×
“On the other hand, striatal plaques showed weak X-34 and 6-CN-PiB fluorescence and lacked a central core [121] indicative of more dispersed and less densely packed Aβ fibrils, characteristic of diffuse plaques [49, 50, 59].”
Nelson, P. T., Alafuzoff, I., Bigio, E. H., Bouras, C., Braak, H., Cairns, N. J., Castellani, R. J., Crain, B. J., Davies, P., Tredici, K. D., et al. (2012) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31825018f7 · Cited by 2,050 · cited 1×
“NFT pathology occurs at a later age than Aβ in DS [76, 78, 81, 93], exhibits an age-related pattern similar to AD [47] and, is a better correlate of cognitive decline and dementia in DS [8, 83, 97, 108].”
Mesulam, M. ‐., Mufson, E. J., Levey, A. I., & Wainer, B. H. (1983) · Journal of Comparative Neurology · doi:10.1002/cne.902140206 · Cited by 1,962
Self-citationPropagation of Tau Pathology in a Model of Early Alzheimer's Disease
de Calignon, A., Polydoro, M., Suárez-Calvet, M., William, C., Adamowicz, D. H., Kopeikina, K. J., Pitstick, R., Sahara, N., Ashe, K. H., Carlson, G. A., et al. (2012) · Neuron · doi:10.1016/j.neuron.2011.11.033 · Cited by 1,427
Acetylcholine as a Neuromodulator: Cholinergic Signaling Shapes Nervous System Function and Behavior
Picciotto, M. R., Higley, M. J., & Mineur, Y. S. (2012) · Neuron · doi:10.1016/j.neuron.2012.08.036 · Cited by 1,404
Arnold, S. E., Hyman, B. T., Flory, J., Damasio, A. R., & Van Hoesen, G. W. (1991) · Cerebral Cortex · doi:10.1093/cercor/1.1.103 · Cited by 1,380
Occurrence of neuropathological changes and dementia of Alzheimer’s disease in Down’s syndrome
Wisniewski, K. E., Wisniewski, H. M., & Wen, G. Y. (1985) · Annals of Neurology · doi:10.1002/ana.410170310 · Cited by 1,159 · cited 1×
“By the age of 40, people with DS exhibit β-amyloid (Aβ) senile plaque and tau-containing neurofibrillary tangle (NFT) pathology [135], cholinergic basal forebrain and brainstem monoaminergic cell loss [79, 80, 82, 136], and neurotrophic deficits [52, 53], that may contribute to the early onset of dementia.”
Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease
Ikonomovic, M. D., Klunk, W. E., Abrahamson, E. E., Mathis, C. A., Price, J. C., Tsopelas, N. D., Lopresti, B. J., Ziolko, S., Bi, W., Paljug, W. R., et al. (2008) · Brain · doi:10.1093/brain/awn016 · Cited by 933 · cited 7×
“Sections were rinsed in KPBS, incubated in 100 µM X-34 for 10 min, dipped in tap water, and incubated in 0.2% NaOH made with 80% EtOH [49] or incubated in 10 µM 6-CN-PiB for 45 min, dipped three times in KPBS followed by a 1-min differentiation in KPBS [50].”
InfluentialSelf-citationCaspase cleavage of tau: Linking amyloid and neurofibrillary tangles in Alzheimer's disease
Gamblin, T. C., Chen, F., Zambrano, A., Abraha, A., Lagalwar, S., Guillozet, A. L., Lu, M., Fu, Y., Garcia-Sierra, F., LaPointe, N., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1630428100 · Cited by 831
The histone deacetylase SIRT6 is a tumor suppressor that controls cancer metabolism
Sebastián, C., Zwaans, B. M. M., Silberman, D. M., Gymrek, M., Goren, A., Zhong, L., Ram, O., Truelove, J., Guimaraes, A. R., Toiber, D., et al. (2012) · Cell · doi:10.1016/j.cell.2012.10.047 · Cited by 660 · cited 1×
“Moreover, gene and protein levels of the epigenetic marker Sirt6, a nuclear deacetylase enzyme involved in DNA repair, tumor suppression, and oxidative stress [71, 74, 120], were increased in DSD + .”
Arendt, T., Stieler, J. T., & Holzer, M. (2016) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2016.08.018 · Cited by 609
Monoclonal antibody AT8 recognises tau protein phosphorylated at both serine 202 and threonine 205
Goedert, M., Jakes, R., & Vanmechelen, E. (1995) · Neuroscience Letters · doi:10.1016/0304-3940(95)11484-e · Cited by 608
Lemere, C. A., Blusztajn, J. K., Yamaguchi, H., Wisniewski, T., Saido, T. C., & Selkoe, D. J. (1996) · Neurobiology of Disease · doi:10.1006/nbdi.1996.0003 · Cited by 584 · cited 1×
“In DS, an increase in soluble Aβ species precedes plaque deposition [42, 121, 127] as early as 21 gestational weeks [42, 121], followed by diffuse deposits of Aβ42 between 8 and 12 years of age, and Aβ40 by the third decade of life, occurring earlier than seen in AD [68, 69, 76].”
Caspase-cleavage of tau is an early event in Alzheimer disease tangle pathology
Rissman, R. A., Poon, W. W., Blurton-Jones, M., Oddo, S., Torp, R., Vitek, M. P., LaFerla, F. M., Rohn, T. T., & Cotman, C. W. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200420640 · Cited by 543 · cited 1×
“The TauC3 epitope is associated with a more mature NFTs, detecting cleavage of tau at the Aspartic421 site by the apoptotic enzyme caspase 3, mainly in fibrillar tau structures [25, 110] after the appearance of tau phosphorylation epitopes [90, 91], and contemporary to the conformational Alz50, which herald the appear…”
Mann, D. M. A., & Esiri, M. M. (1989) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(89)90019-1 · Cited by 471
Alafuzoff, I., Arzberger, T., Al‐Sarraj, S., Bodi, I., Bogdanovic, N., Braak, H., Bugiani, O., Del‐Tredici, K., Ferrer, I., Gelpi, E., et al. (2008) · Brain Pathology · doi:10.1111/j.1750-3639.2008.00147.x · Cited by 467 · cited 1×
“Unlike pS422, which marks phosphorylation at the C-terminal domain [125], AT8 detects phosphorylated amino acids in the middle, proline-rich region of the tau epitope [38] and is associated with a more severe stage of AD [1].”
Klunk, W. E., Price, J. C., Mathis, C. A., Tsopelas, N. D., Lopresti, B. J., Ziolko, S. K., Bi, W., Hoge, J. A., Cohen, A. D., Ikonomovic, M. D., et al. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.0730-07.2007 · Cited by 389
Amargos-Bosch, M. (2004) · Cerebral Cortex · doi:10.1093/cercor/bhg128 · Cited by 370
Aging in Down Syndrome and the Development of Alzheimer's Disease Neuropathology
Head, E., T. Lott, I., M. Wilcock, D., & A. Lemere, C. (2015) · Current Alzheimer Research · doi:10.2174/1567205012666151020114607 · Cited by 289
Synaptic Tau Seeding Precedes Tau Pathology in Human Alzheimer’s Disease Brain
DeVos, S. L., Corjuc, B. T., Oakley, D. H., Nobuhara, C. K., Bannon, R. N., Chase, A., Commins, C., Gonzalez, J. A., Dooley, P. M., Frosch, M. P., et al. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00267 · Cited by 285 · cited 1×
“The greater number of NFTs displaying Serine422 in FC and striatum suggests that phosphorylation of tau at this site is an early event in tau pathogenesis in DS [19, 21, 48].”
Overexpression of Dyrk1A contributes to neurofibrillary degeneration in down syndrome
Liu, F., Liang, Z., Wegiel, J., Hwang, Y., Iqbal, K., Grundke‐Iqbal, I., Ramakrishna, N., & Gong, C. (2008) · The FASEB Journal · doi:10.1096/fj.07-104539 · Cited by 272 · cited 2×
“However, we found numerous cortical NFT profiles that displayed both TauC3 and pS422 in DSD + cases, suggesting that these posttranslational events occur close in time, perhaps, associated with an upregulation of Down syndrome critical region 1 (DSCR1) [23, 123] and tyrosine phosphorylation-regulated kinase1 ( DYRK1)…”
Intraneuronal Aβ-Amyloid Precedes Development of Amyloid Plaques in Down Syndrome
Gyure, K. A., Durham, R., Stewart, W. F., Smialek, J. E., & Troncoso, J. C. (2001) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2001-125-0489-iaapdo · Cited by 248
Gene expression profiling in the adult Down syndrome brain
Lockstone, H. E., Harris, L. W., Swatton, J. E., Wayland, M. T., Holland, A. J., & Bahn, S. (2007) · Genomics · doi:10.1016/j.ygeno.2007.08.005 · Cited by 240 · cited 5×
“We found that the expression levels of the cholesterol carrier Apoe, which is involved in Aβ production via α-secretase regulation [122], were comparable between DS groups, while Apoe gene expression upregulation was seen in the prefrontal cortex between DS and controls [73].”
InfluentialMiner, L. A. H., Backstrom, J. R., Sanders-Bush, E., & Sesack, S. R. (2003) · Neuroscience · doi:10.1016/s0306-4522(02)00580-8 · Cited by 216
Leverenz, J. B., & Raskind, M. A. (1998) · Experimental Neurology · doi:10.1006/exnr.1997.6777 · Cited by 214
Genetic and host factors for dementia in Down's syndrome
Schupf, N. (2002) · British Journal of Psychiatry · doi:10.1192/bjp.180.5.405 · Cited by 188 · cited 1×
“In addition, individuals with DS exhibit characteristics of premature aging and are at high risk for developing dementia of the Alzheimer’s disease (AD) -type several decades earlier than seen in sporadic AD [118, 137, 138].”
Low PiB PET retention in presence of pathologic CSF biomarkers in Arctic APP mutation carriers
Schöll, M., Wall, A., Thordardottir, S., Ferreira, D., Bogdanovic, N., Långström, B., Almkvist, O., Graff, C., & Nordberg, A. (2012) · Neurology · doi:10.1212/wnl.0b013e31825fdf18 · Cited by 169 · cited 1×
“These observation are consistent with autopsy [50, 98] and in vivo PET imaging studies using [11C]PiB in DS [4, 44, 45, 64–66, 130], familial [61, 62, 85, 109, 111, 116, 132], and sporadic AD [51, 58, 60, 115].”
Gray matter atrophy pattern in elderly with subjective memory impairment
Peter, J., Scheef, L., Abdulkadir, A., Boecker, H., Heneka, M., Wagner, M., Koppara, A., Klöppel, S., Jessen, F., & Initiative, A. D. N. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.05.1764 · Cited by 165
Margallo‐Lana, M. L., Moore, P. B., Kay, D. W. K., Perry, R. H., Reid, B. E., Berney, T. P., & Tyrer, S. P. (2007) · Journal of Intellectual Disability Research · doi:10.1111/j.1365-2788.2006.00902.x · Cited by 145 · cited 2×
“However, despite consistent and profuse neuropathology, only two-thirds of all adult cases with DS develop dementia [37, 83, 139].”
Vana, L., Kanaan, N. M., Ugwu, I. C., Wuu, J., Mufson, E. J., & Binder, L. I. (2011) · The American Journal of Pathology · doi:10.1016/j.ajpath.2011.07.044 · Cited by 138 · cited 3×
“We also found that AT8 and pS422 positive NTs were higher than those displaying tau conformational changes in DSD + , suggesting that phosphorylated tau epitopes are an early pathogenic events associated with cognitive deficits in DS similar to AD [104, 131].”
Self-citationNeuronal exosomes reveal Alzheimer's disease biomarkers in Down syndrome
Hamlett, E. D., Goetzl, E. J., Ledreux, A., Vasilevko, V., Boger, H. A., LaRosa, A., Clark, D., Carroll, S. L., Carmona‐Iragui, M., Fortea, J., et al. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.08.012 · Cited by 129 · cited 13×
“No differences were found between double- and triple-labeled NFT numbers in the DSD- group.”
InfluentialSelf-citationIulita, M. F., Ower, A., Barone, C., Pentz, R., Gubert, P., Romano, C., Cantarella, R. A., Elia, F., Buono, S., Recupero, M., et al. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.05.001 · Cited by 99
Tau‐66: evidence for a novel tau conformation in Alzheimer's disease
Ghoshal, N., García‐Sierra, F., Fu, Y., Beckett, L. A., Mufson, E. J., Kuret, J., Berry, R. W., & Binder, L. I. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00346.x · Cited by 97 · cited 1×
“The evolution of NFTs follows a linear progression where tau undergoes posttranslational phosphorylation, conformation, and truncation events in AD [5, 9, 26, 28, 41, 131] where tau phosphorylation occurs early [90, 91] and correlates with AD severity [104, 131].”
Self-citationGinsberg, S. D., Elarova, I., Ruben, M., Tan, F., Counts, S. E., Eberwine, J. H., Trojanowski, J. Q., Hemby, S. E., Mufson, E. J., & Che, S. (2004) · Neurochemical Research · doi:10.1023/b:nere.0000023593.77052.f7 · Cited by 97 · cited 3×
“Following the hybridization protocol, arrays were washed sequentially in 2× SSC/0.1% SDS, 1× SSC/0.1% SDS and 0.5× SSC/0.1% SDS for 15 min each at 37 °C. Arrays were placed in a phosphor screen for 24 h and developed on a phosphor imager (Storm 840, GE Healthcare, Piscataway, NJ).”
InfluentialSelf-citationPerez, S. E., Raghanti, M. A., Hof, P. R., Kramer, L., Ikonomovic, M. D., Lacor, P. N., Erwin, J. M., Sherwood, C. C., & Mufson, E. J. (2013) · Journal of Comparative Neurology · doi:10.1002/cne.23428 · Cited by 95 · cited 1×
“X-34 and 6-CN-PiB histofluorescence was used to assess amyloid burden in the FC and striatum [105].”
Self-citationToledo, J. B., Bjerke, M., Da, X., Landau, S. M., Foster, N. L., Jagust, W., Jack, C., Weiner, M., Davatzikos, C., Shaw, L. M., et al. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2014.4829 · Cited by 88
Kida, E., Choi-Miura, N.-H., & Wisniewski, K. E. (1995) · Brain Research · doi:10.1016/0006-8993(95)00482-6 · Cited by 79 · cited 1×
“On the other hand, striatal plaques showed weak X-34 and 6-CN-PiB fluorescence and lacked a central core [121] indicative of more dispersed and less densely packed Aβ fibrils, characteristic of diffuse plaques [49, 50, 59].”
Perez, S. E., Sherwood, C. C., Cranfield, M. R., Erwin, J. M., Mudakikwa, A., Hof, P. R., & Mufson, E. J. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.12.017 · Cited by 50
Self-citation
Cited by
Alzheimer's disease associated with Down syndrome: a genetic form of dementia
Fortea, J., Zaman, S. H., Hartley, S., Rafii, M. S., Head, E., & Carmona-Iragui, M. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00245-3 · Cited by 357
Gourmaud, S., Shou, H., Irwin, D. J., Sansalone, K., Jacobs, L. M., Lucas, T. H., Marsh, E. D., Davis, K. A., Jensen, F. E., & Talos, D. M. (2020) · Brain · doi:10.1093/brain/awz381 · Cited by 155
“tive impairment, such as Down syndrome and fragile X syndrome (Westmark et al., 2016; Perez et al., 2019).”
BackgroundEvolution of neuroinflammation across the lifespan of individuals with Down syndrome
Flores-Aguilar, L., Iulita, M. F., Kovecses, O., Torres, M. D., Levi, S. M., Zhang, Y., Askenazi, M., Wisniewski, T., Busciglio, J., & Cuello, A. C. (2020) · Brain · doi:10.1093/brain/awaa326 · Cited by 138
Further understanding the connection between Alzheimer's disease and Down syndrome
Snyder, H. M., Bain, L. J., Brickman, A. M., Carrillo, M. C., Esbensen, A. J., Espinosa, J. M., Fernandez, F., Fortea, J., Hartley, S. L., Head, E., et al. (2020) · Alzheimer's & Dementia · doi:10.1002/alz.12112 · Cited by 105
Self-citationMartini, A. C., Helman, A. M., McCarty, K. L., Lott, I. T., Doran, E., Schmitt, F. A., & Head, E. (2020) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1002/dad2.12113 · Cited by 66
Self-citation
Metadata
- Authors
- Perez, S. E., Miguel, J. C., He, B., Malek-Ahmadi, M., Abrahamson, E. E., Ikonomovic, M. D., Lott, I., Doran, E., Alldred, M. J., Ginsberg, S. D., & Mufson, E. J.
- Venue
- Acta Neuropathologica
- Published
- 2019-02-07
- Volume
- 137
- Issue
- 3
- Pages
- 413-436
- ISSN
- 0001-6322 (ISSN-L)
- 1432-0533
- OpenAlex
- W2913127423
- Cited by
- 49
- References
- 39
- FWCI
- 3.57
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.